KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash from Financing Activities (2017 - 2025)

Historic Cash from Financing Activities for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $81.4 million.

  • Aquestive Therapeutics' Cash from Financing Activities rose 47898823.53% to $81.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.1 million, marking a year-over-year increase of 1690.48%. This contributed to the annual value of $83.6 million for FY2024, which is 200347.26% up from last year.
  • Per Aquestive Therapeutics' latest filing, its Cash from Financing Activities stood at $81.4 million for Q3 2025, which was up 47898823.53% from -$100000.0 recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Cash from Financing Activities registered a high of $81.7 million during Q1 2024, and its lowest value of -$9.2 million during Q1 2023.
  • Its 5-year average for Cash from Financing Activities is $12.2 million, with a median of $4.3 million in 2023.
  • In the last 5 years, Aquestive Therapeutics' Cash from Financing Activities tumbled by 80916.8% in 2023 and then surged by 47898823.53% in 2025.
  • Aquestive Therapeutics' Cash from Financing Activities (Quarter) stood at $5.5 million in 2021, then plummeted by 95.71% to $234000.0 in 2022, then soared by 1572.22% to $3.9 million in 2023, then tumbled by 95.99% to $157000.0 in 2024, then skyrocketed by 51754.14% to $81.4 million in 2025.
  • Its Cash from Financing Activities stands at $81.4 million for Q3 2025, versus -$100000.0 for Q2 2025 and $20.6 million for Q1 2025.